The Pulmonary Fibrosis Foundation has just published November’s schedule of ongoing fundraising events. With 10 different programs for getting involved to choose from this month, it should be easy to find something right up your alley, and help support research and development efforts for pulmonary fibrosis, as…
As the drug development community continues to invest into pulmonary fibrosis research, new insights are improving both diagnostic and prognostic tools for improving treatment of the disease. Recently, Pacific Therapeutics Ltd. scientists reported in a study entitled “Familial and sporadic idiopathic pulmonary fibrosis:making the diagnosis from peripheral blood”…
Pattern of alveolar oxygen exchange units on the surface of a mouse lung. Credit: Dr. Shou Ping Guan A recent study led by Professors Frank McKeon, Ph.D., and Wa Xian, Ph.D. from The Jackson Laboratory focused on a novel lung regeneration concept and how certain lung stem…
A new study on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) entitled “Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis” was published in Respiratory Research by Keishi Oda, part of Dr. Hiroshi Mukae’s group from the Department of Respiratory Medicine at University of Occupational and…
New stem cell research is offering insights into how scientists may someday be able to mitigate lung injury caused by diseases such as IPF. A recent study entitled “The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor” and published…
The Scleroderma Research Foundation will host a free, live webinar on the relationship between pulmonary fibrosis (PF) and scleroderma on Thursday, November 13, at 10:00 a.m. PST. The Director of Biological Research for the Interstitial Lung Disease Program at University of California San Francisco (UCSF), Paul Wolters, will be the main lecturer…
The chief executive officer and president of Pacific Therapeutics, a clinical stage specialty pharmaceutical company dedicated to the development of treatments for fibrosis and erectile dysfunction, commented on the recent interest of big pharmaceutical companies in acquiring therapies for the treatment of fibrosis. Doug Unwin said that…
The National Institutes of Health (NIH) recently granted a $15.6 million award to The University of North Carolina, Chapel Hill (UNC-CH) and The University of Colorado, Denver (UCD), to support five years of research on mucolytic agents. The agents were discovered by the developmental stage biopharmaceutical company Parion Sciences,…
Two subsidiaries of Omnicare Specialty Care Group (SCG) recently announced they have been chosen to provide services to idiopathic pulmonary fibrosis (IPF) patients taking OFEV® (nintedanib), a recently-approved tyrosine kinase inhibitor developed by Boehringer Ingelheim. RxCrossroads and Advanced Care Scripts (ACS) have been selected to carry out reimbursement…
In a study entitled “Development of microscopic polyangiitis-related pulmonary fibrosis in a patient with autoimmune pulmonary alveolar proteinosis” published in BMC Pulmonary Medicine the authors report the first evidence of a relationship between ANCA-associated systemic vasculitis and aPAP-related pulmonary fibrosis. Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare…
Get regular updates to your inbox.
